Sentinel Node Identification in melanoma: current clinical impact, new emerging SPECT radiotracers and technological advancements. An update of the last decade.
Melanoma is the most lethal skin cancer with a mortality rate of 262 cases per 100.000 cases. The sentinel lymph node (SLN) is the first lymph node draining the tumor. SLN biopsy is a widely accepted procedure in the clinical setting since it provides important prognostic information, helps patient management and avoids the side effects of complete lymph node dissection. The rationale of identifying and removing the SLN relies on the low probability of subsequent metastatic nodes in case of a negative histological exam performed in the SLN. Recently, new analytical approaches, based on the evaluation of scintigraphic images are exploring also the possibility to predict the metastatic involvement of the SLN. 99mTc-labeled colloids are still the most used radiotracers but new promising radiotracers, such as 99mTc-Tilmanocept, are now on the market. In the last decades, single photon emission computed tomography-computerized tomography (SPECT/CT) has gained wider diffusion in clinical departments and there is large evidence about its superior diagnostic accuracy over planar lymphoscintigraphy (PL) in the detection of SLN in patients with melanoma. Scientists are investigating also new hybrid techniques combining functional and anatomical images for the depiction of SLN but further evidence about their value is needed. This review examined the predictive and prognostic factors of lymphoscintigraphy for metastatic involvement of SLN, the currently available and emerging radiotracers and the evidence of the additional value of SPECT/CT over PL for the identification of SLN in patients with melanoma. Finally, the review discussed the most recent technical advances in the field.